Peptide YY3-36 - Gila Therapeutics

Drug Profile

Peptide YY3-36 - Gila Therapeutics

Alternative Names: GT 001 - Gila Therapeutics; GT 002 - Gila Therapeutics; GT 003 - Gila Therapeutics; GT-001; GT-002; GT-003; Peptide YY (3-36); Peptide YY3-36; PYY(3-36); PYY3-36

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gila Therapeutics
  • Class Antihyperglycaemics; Hormones; Obesity therapies; Peptides
  • Mechanism of Action Peptide YY (3-36)-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Obesity
  • Research Diabetes mellitus

Most Recent Events

  • 19 Jun 2018 PYY3-36 - Gila Therapeutics is available for licensing as of 19 Jun 2018.http://gilatherapeutics.com/contact-us/
  • 19 Jun 2018 Early research in Diabetes mellitus in USA (PO)(Gila therapeutics, Pipeline June 2018)
  • 19 Jun 2018 Gila therapeutics plans a phase-I trial for GT 002 in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top